Video Center


The OBR Video Center Features educational videos covering a wide range of oncology specific topics.

Eunice Wang, MD, regarding evolving treatment considerations for FLT3 mutated AML

Dr. Wang discusses some of the evolving treatment considerations for FLT3 mutated acute myeloid leukemia (AML) patients who have failed prior TKI therapy

Published: 18 June 2018

Recent Videos: Leukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)

video

Eunice Wang, MD, tells us about the most exciting data coming out of the 2018 ASCO Annual Meeting

Dr. Wang offers opinion on exciting data coming out of the 2018 ASCO Annual Meeting

video

Eunice Wang, MD, on the role of nivolumab maintenance in high-risk AML patients

Dr. Wang discusses whether there is a role for nivolumab maintenance in high-risk acute myeloid leukemia (AML) patients

video

Eunice Wang, MD, regarding evolving treatment considerations for FLT3 mutated AML

Dr. Wang discusses some of the evolving treatment considerations for FLT3 mutated acute myeloid leukemia (AML) patients who have failed ...

video

Eunice Wang, MD, shares what we've learned about gilteritinib since the 2017 ASCO Annual Meeting

Dr. Wang elaborates on what we've learned about gilteritinib in FLT3-ITD mutated acute myeloid leukemia (AML) patients

video

Eunice Wang, MD, considers the potential impact of gilteritinib in patients with FLT3-ITD AML

Dr. Wang regarding the potential impact of gilteritinib as maintenance therapy after allogenic hematopoietic stem cell transplantation in patients with ...

video

Eunice Wang, MD, on next-generation sequencing and treatment selection in AML

Dr. Wang considers the impact of next-generation sequencing on treatment selection in acute myeloid leukemia (AML)

video

Mark Levis, MD, PhD, discusses exciting data from the 2018 ASCO Annual Meeting

Dr. Levis offers his opinion on the most exciting clinical trial data coming out of the 2018 ASCO Annual Meeting

video

Mark Levis, MD, PhD, speculates on evolving treatment considerations for FLT3 mutated AML

Dr. Levis tells us about the evolving treatment considerations for FLT3 mutated acute myeloid leukemia (AML) patients who have failed ...

video

Mark Levis, MD, PhD, discusses what we've learned about gilteritinib in FLT3 mutated AML patients

Dr. Levis shares what new information we've learned about gilteritinib in FLT3 mutated acute myeloid leukemia (AML)

video

Mark Levis, MD, PhD, comments on measurable residual disease in relapsed/refractory AML

Dr. Levis elaborates on the impact of measurable residual disease in the clinical outcomes of patients with relapsed or refractory ...

Related Videos

video-image

Eunice Wang, MD, tells us about the most exciting data coming out of the 2018 ASCO Annual Meeting

video-image

Eunice Wang, MD, on the role of nivolumab maintenance in high-risk AML patients

video-image

Eunice Wang, MD, shares what we've learned about gilteritinib since the 2017 ASCO Annual Meeting

video-image

Eunice Wang, MD, considers the potential impact of gilteritinib in patients with FLT3-ITD AML

video-image

Eunice Wang, MD, on next-generation sequencing and treatment selection in AML

video-image

Mark Levis, MD, PhD, discusses exciting data from the 2018 ASCO Annual Meeting

video-image

Mark Levis, MD, PhD, speculates on evolving treatment considerations for FLT3 mutated AML

video-image

Mark Levis, MD, PhD, discusses what we've learned about gilteritinib in FLT3 mutated AML patients

video-image

Mark Levis, MD, PhD, comments on measurable residual disease in relapsed/refractory AML

video-image

Mark Levis, MD, PhD, on factors influencing 1st line therapy in AML patients with FLT3 mutations

video-image

Mark Levis, MD, PhD, regarding the impact of next-generation sequencing in AML

video-image

Andrew Lane, MD, PhD, describes the efficacy outcomes of SL-401 consolidation therapy in AML

video-image

Ching-Hon Pui, MD, speculates on the use of CAR T-cell therapy in pediatric ALL patients

video-image

Ching-Hon Pui, MD, explains how precision medicine is changing the way pediatric ALL is treated

video-image

Ching-Hon Pui, MD, on whether the FDA should accept minimal residual disease as a surrogate endpoint

video-image

Ching-Hon Pui, MD, discusses minimal residual disease in pediatric and adult ALL patients

video-image

Jorge Cortes, MD, shares data presented at ASH 2017 regarding bosutinib in CML treatment

video-image

Andrew Lane, MD, PhD, on how frequently clinicians interact with frail AML patients

video-image

Andrew Lane, MD, PhD, on treatment approaches when managing frail AML patients

video-image

Andrew Lane, MD, PhD, offers strategies for clinicians when treating frail AML patient populations

video-image

Jorge Cortes, MD, on what was discussed at ASH 2017 regarding treatment discontinuation in AML

video-image

Edward A. Copelan, MD, shares highlights from ASH 2017 regarding treatment of acute myeloid leukemia

video-image

Edward A. Copelan, MD, considers whether azacitidine can be used for induction in AML

video-image

Keith Pratz, MD, on the proportion of AML patients who fall into the frail category

video-image

Keith Pratz, MD, explains how he is incorporating Vyxeos into his treatment of AML patients

video-image

Keith Pratz, MD, suggests strategies for clinicians when treating frail AML patients

video-image

Keith Pratz, MD, on exciting clinical data regarding FTL3 tyrosine kinase inhibitors in AML patients

video-image

Keith Pratz, MD, shares the outcome of the venetoclax study in treatment-naive AML patients

video-image

Keith Pratz, MD, on combining ivosidenib or enasidenib with chemotherapy in AML

video-image

Keith Pratz, MD, tells us about the epidemiology and cytogenetic risk associated with AML

video-image

Andrew Lane, MD, PhD, on minimal residual disease and AML treatment decisions

video-image

Habte Yimer, MD, considers the impact of combination obinutuzumab and bendamustine on CLL patients

video-image

Eunice Wang, MD, shares exciting data for acute myeloid leukemia (AML) presented at ASH 2017

video-image

Eunice Wang, MD, considers approaches for clinicians when managing frail AML patients

video-image

Eunice Wang, MD, on incorporating Vyxeos (liposomal daunorubicin and cytarabine) in AML treatment

video-image

Eunice Wang, MD, on strategies for frail AML patients who do not qualify for intensive therapy

video-image

Eunice Wang, MD, on how minimal residual disease is being integrated into treatment decisions in AML

video-image

Michael Boxer, MD, on how obinutuzumab and bendamustine impacts quality of life in CLL patients

video-image

Michael Boxer, MD, considers broader uses for fostamatinib

video-image

C. Ola Landgren, MD, discusses risk factors for developing AML or MDS after treatment of MM

video-image

Gary Gordon, MD, PhD, discusses safety concerns in the phase 3 MURANO clinical trial

video-image

Gary Gordon, MD, PhD, discusses efficacy results of the phase 3 MURANO clinical trial

video-image

Bruce D. Cheson, MD, discusses care, toxicities, and outcomes treating CLL patients with venetoclax

video-image

Bruce D. Cheson, MD on choosing a front-line therapeutic regimen for CLL patients

video-image

Matthew Davids, MD discusses how he typically treats front line CLL outside of a clinical study

video-image

Bruce D. Cheson, MD discusses the efficacy and safety of acalabrutinib in relapsed/refractory MCL

video-image

John P. Leonard, MD discusses lenalidomide plus rituximab for the treatment of MCL

video-image

Will Tomorrow's CAR-T Therapy Innovations Solve Today's Challenges?

video-image

How Can Manufacturers Help Institutions Prepare for CAR-T Therapies?

video-image

How Can a CAR-T Center Get Established and Effectively Treat Patients?

video-image

Sai-Hong Ignatius Ou, MD, PhD, comments on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, on pemetrexed maintenance therapy

video-image

Sai-Hong Ignatius Ou, MD, PhD, discusses key takeaways from the IMpower150 study at ASCO 2018

video-image

Sai-Hong Ignatius Ou, MD, PhD, comments on combo chemotherapy & immunotherapy in 2nd line NSCLC

video-image

Sai-Hong Ignatius Ou, MD, PhD, regarding combo chemotherapy & immunotherapy in 1st line NSCLC

video-image

Benjamin Philip Levy, MD, on Tumor Mutation Burden (TMB) as a biomarker in NSCLC

video-image

Benjamin Philip Levy, MD, on maintenance therapy following carboplatin, pemetrexed & pembrolizumab

video-image

Benjamin Philip Levy, MD, comments on the IMpower150 clinical trial in NSCLC

video-image

Benjamin Philip Levy, MD, on options for NSCLC patients who progress on 1st line I-O & chemotherapy

video-image

Benjamin Philip Levy, MD, regarding combo chemotherapy & immunotherapy in 2nd line NSCLC

video-image

Benjamin Philip Levy, MD, discusses the practice-changing outcomes from Keynote 189

video-image

Benjamin Philip Levy, MD, offers opinion on testing for PD-L1 expression in NSCLC

video-image

Novel Endpoints: Working Through Today's Challenges to Improve the Future of Cancer Care

video-image

Novel Endpoints in Cancer Care: What Lies Ahead

video-image

Oncology Clinical Trials: Why We're Searching for Emerging Endpoints

video-image

Howard (Jack) West, MD, regarding Tumor Mutation Burden (TMB) as a biomarker for NSCLC patients

video-image

Howard (Jack) West, MD, on maintenance therapy after carboplatin, pemetrexed & pembrolizimab

video-image

NGS and Cancer: Combatting the Hazards of Misinformation

video-image

Will NGS-Based Cancer Tests Become Routine?

video-image

Next-Gen Sequencing is Transforming Oncology Practices

video-image

Howard (Jack) West, MD, discusses key takeaways from the IMpower150 study in NSCLC

video-image

Howard (Jack) West, MD, on treatment options for patients who progress on I-O & chemotherapy

video-image

Howard (Jack) West, MD, regarding the combination of immunotherapy & chemotherapy in NSCLC

video-image

Howard (Jack) West, MD, regarding PDL-1 expression and NSCLC

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, considers predictive biomarkers in NSCLC

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, comments on the TAILORx study from ASCO 2018

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, on the outcomes of the PERSEPHONE clinical trial

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, regarding novel concepts in clinical trial design

video-image

Howard A. "Skip" Burris III, MD, FACP, FASCO, shares his goals for the 2019 ASCO Annual Meeting

video-image

Neelima Denduluri, MD, on the outcomes of the SANDPIPER study presented at ASCO 2018

video-image

Neelima Denduluri, MD, looks back on the Short-HER trial from the 2017 ASCO Annual Meeting

video-image

Neelima Denduluri, MD, offers opinion on the PERSEPHONE trial in early HER2+ breast cancer

video-image

Neelima Denduluri, MD, tells us about the recent updates to breast cancer guidelines

video-image

Neelima Denduluri, MD, comments on the role of CDK4/6 inhibitors

video-image

Neelima Denduluri, MD, regarding the implications of the TAILORx study from ASCO 2018

video-image

Robert A. Figlin, MD, on the convenience factor of oral TKIs & treatment decisions in advanced RCC

video-image

Robert A. Figlin, MD, on the trade-offs between safety & efficacy when discussing 1st line RCC

video-image

Robert A. Figlin, MD, provides perspective on I-O failures

video-image

Robert A. Figlin, MD, on deciding which metastatic RCC patients should get a TKI as 1st line therapy

video-image

Robert A. Figlin, MD, on how checkpoint inhibitors figure into treatment for 1st line RCC patients

video-image

Walter Stadler, MD, on therapies for high-volume, metastatic castration-resistant prostate cancer

video-image

Walter Stadler, MD, on immunotherapy and prostate cancer treatment algorithms

video-image

Walter Stadler, MD, comments on the PROSPER & SPARTAN studies in prostate cancer

video-image

Walter Stadler, MD, regarding TKIs in the treatment of renal cell carcinoma

video-image

Walter Stadler, MD, on treating RCC in the 2nd line setting following I-O failure

video-image

Walter Stadler, MD, considers which mRCC patients should receive a TKI as 1st line therapy

video-image

David I. Quinn, MD, provides perspective on the trade-offs between safety & efficacy in 1st line RCC

video-image

David I. Quinn, MD, considers whether the convenience of oral TKIs impacts RCC treatment

video-image

David I. Quinn, MD, comments on 2nd line therapy options following I-O failure

video-image

David I. Quinn, MD, shares thoughts on Keynote 427 from the 2018 ASCO Annual Meeting

video-image

David I. Quinn, MD, regarding the most exciting RCC data coming out of ASCO 2018

video-image

Jeanny B. Aragon-Ching, MD, FACP, shares how checkpoint inhibitors fit into RCC treatment algorithms

video-image

Jeanny B. Aragon-Ching, MD, FACP, comments on 2nd line treatment options in RCC after I-O failure

video-image

Jeanny B. Aragon-Ching, MD, FACP, on response rates for erdafitinib in metastatic bladder cancer

video-image

Jeanny B. Aragon-Ching, MD, FACP, on molecular markers in high-risk muscle-invasive bladder cancer

video-image

Jeanny B. Aragon-Ching, MD, FACP, discusses new guidelines in treatment of metastatic bladder cancer

video-image

Jeanny B. Aragon-Ching, MD, FACP, regarding the impact of the PROSPER and SPARTAN clinical trials

video-image

Mohammad Jahanzeb, MD, FACP, discusses the significance of Keynote 42 from ASCO 2018

video-image

Mohammad Jahanzeb, MD, FACP, regarding pemetrexed maintenance therapy

video-image

Mohammad Jahanzeb, MD, FACP, on the results of Keynote 189, PDL-1 expression and patient selection

video-image

Neelima Denduluri, MD, speculates on the implications of taselisib data at ASCO 2018

video-image

Neelima Denduluri, MD, on the MONALEESA-3 study in HR+/HER2- advanced breast cancer

video-image

Neelima Denduluri, MD, considers whether the results of TAILORx are practice-changing

video-image

Gary D. Steinberg, MD, on whether FGFR inhibitors have the potential to be practice-changing

video-image

Bobby Green, MD, on next-generation sequencing and Flatiron's clinico-genomic database

video-image

Bobby Green, MD, shares an update on Flatiron’s clinico-genomic database

video-image

Bobby Green, MD, reflects on the 2018 ASCO Annual Meeting

video-image

Ghassan Abou-Alfa, MD, MBA, regarding the shortcomings of the RECIST study in HCC

video-image

Ghassan Abou-Alfa, MD, MBA, shares the outcomes of the CELESTIAL study from ASCO 2018

video-image

Ghassan Abou-Alfa, MD, MBA, considers how immunotherapies should be combined with TKIs

video-image

Ghassan Abou-Alfa, MD, MBA, on the latest in systemic therapy for advanced HCC

video-image

Atrayee Basu Mallick, MD, shares highlights from the 2018 ASCO Annual Meeting

video-image

Atrayee Basu Mallick, MD, considers how tumor-sidedness impacts CRC treatment algorithms

video-image

Atrayee Basu Mallick, MD, discusses how nivolumab is incorporated into mCRC treatment algorithms

video-image

Atrayee Basu Mallick, MD, tells us about the outcomes of the Checkmate 142 study in mCRC

video-image

Atrayee Basu Mallick, MD, on the addition of vemurafenib to the NCCN guidelines for mCRC

video-image

Atrayee Basu Mallick, MD, regarding the impact of stage & mismatch repair status on CRC treatment

video-image

Atrayee Basu Mallick, MD, offers opinion on immunotherapy in colorectal cancer

video-image

John Leighton, MD, on the headline “Immunotherapy Now Standard for Some Patients With CRC”

video-image

John Leighton, MD, regarding preoperative chemotherapy in resectable pancreatic cancer

video-image

John Leighton, MD, regarding the PA.6 clinical study presented at ASCO 2018

video-image

John Leighton, MD, explains how tumor sidedness impacts CRC treatment algorithms

video-image

John Leighton, MD, comments on the outcomes of Checkmate 142 in mCRC

video-image

Howard Hochster, MD, regarding the outcomes of the PRODIGY7 study in mCRC

video-image

Howard Hochster, MD, comments on the VALENTINO study presented at ASCO 2018

video-image

Howard Hochster, MD, tells us about the outcomes of ECOG-7208 in 2nd line mCRC

video-image

Primo N. Lara, Jr., MD, comments on which TKIs appear most effective in 1st line RCC

video-image

Primo N. Lara, Jr., MD, on whether the convenience of oral TKIs influences treatment decisions

video-image

Primo N. Lara, Jr., MD, considers the trade-offs between safety & efficacy in 1st line RCC treatment

video-image

Primo N. Lara, Jr., MD, regarding the treatment path following I-O failure

video-image

Primo N. Lara, Jr., MD, on deciding which mRCC patients should receive a TKI

video-image

Primo N. Lara, Jr., MD, on how checkpoint inhibitors fit into RCC treatment algorithms

video-image

Celestia S. Higano, MD, considers the role of immunotherapy in prostate cancer

video-image

Celestia S. Higano, MD, discusses outcomes from the PROSPER and SPARTAN studies at ASCO 2018

video-image

Edgardo S. Santos, MD, FACP, on the benefits of combination docetaxel + ramucirumab

video-image

Edgardo S. Santos, MD, FACP, regarding pemetrexed maintenance therapy

video-image

Edgardo S. Santos, MD, FACP, on the outcomes of Keynote 189 in metastatic NSCLC

video-image

Edgardo S. Santos, MD, FACP, discusses exciting developments out of ASCO 2018

video-image

Brian I. Rini, MD, FACP, comments on the CARMENA study presented at ASCO 2018

video-image

Brian I. Rini, MD, FACP, discusses the influence of the convenience of oral TKIs

video-image

Brian I. Rini, MD, FACP, regarding the trade-offs between safety & efficacy in 1st line RCC

video-image

Brian I. Rini, MD, FACP, considers 2nd line treatment in advanced RCC following I-O failure

video-image

Brian I. Rini, MD, FACP, on which metastatic RCC patients should receive a TKI as 1st line therapy

video-image

Brian I. Rini, MD, FACP, on how checkpoint inhibitors figure into treatment algorithms for RCC

video-image

James A. Posey III, MD, on the outcomes of the LAPACT study in locally advanced pancreatic cancer

video-image

James A. Posey III, MD, comments on the impact of immunotherapy agents in pancreatic cancer

video-image

James A. Posey III, MD, discusses the unmet medical needs in pancreatic ductal adenocarcinoma

video-image

James A. Posey III, MD, offers opinion on preoperative chemotherapy in resectable pancreatic cancer

video-image

James A. Posey III, MD, on the results and implications of the PA.6 clinical trial from ASCO 2018

video-image

Ivo Abraham, PhD, RN, comments on how we can demonstrate the value of cancer treatments

video-image

Ivo Abraham, PhD, RN, outlines biosimilar pricing and reimbursement

video-image

Ivo Abraham, PhD, RN, discusses those biosimilars that are approved or close to approval

video-image

Ivo Abraham, PhD, RN, speculates on the hurdles that could prevent the adoption of biosimilars

video-image

Ivo Abraham, PhD, RN, explains the key features of a biosimilar

video-image

Randall A. Oyer, MD, considers the work being done to address disparities in healthcare

video-image

Randall A. Oyer, MD, provides information on the ACCC Immuno-Oncology Institute

video-image

Randall A. Oyer, MD, explains how ACCC is interpreting the data on genetics presented at ASCO 2018

video-image

Roy S. Herbst, MD, PhD, discusses the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC

video-image

Roy S. Herbst, MD, PhD, discusses drug sequencing as a result of Keynote 189 and 42 results

video-image

Roy S. Herbst, MD, PhD, on if patient selection will change as a result of Keynote 42

video-image

Roy S. Herbst, MD, PhD, on pemextrexed maintenance treatment

video-image

Roy S. Herbst, MD, PhD, shares what's exciting here at ASCO 2018

video-image

Roy S. Herbst, MD, PhD, on if Keynote 189 impacted view of PDL-1 expression and patient selection

video-image

Lisa Rometty on the collaboration between Watson and the VA Precision Oncology Program

video-image

Lisa Rometty shares some of the recent accomplishments of IBM's Watson

video-image

Lisa Rometty elaborates on Watson's role in clinical trial matching

video-image

Lisa Rometty regarding the impact of Watson on real-world evidence and clinical decision making

video-image

Lisa Rometty explains how augmented intelligence is helping oncologists better treat cancer patients

video-image

Julie Gralow, MD, speculates on taselisib as a standard of care based on the results of SANDPIPER

video-image

Julie Gralow, MD, tells us about the SANDPIPER proof of concept trial presented at ACSO 2018

video-image

Julie Gralow, MD, comments on the practice-changing implications of the TAILORx study

video-image

Julie Gralow, MD, discusses outcomes from the TAILORx study presented at ASCO 2018

video-image

Julie Gralow, MD, regarding the reduction in cardiac events in the PERSEPHONE study

video-image

Julie Gralow, MD, reflects on the PERSEPHONE trial from the 2018 ASCO Annual Meeting

video-image

Julie Gralow, MD, on the implications of the PERSEPHONE trial in early HER2+ breast cancer

video-image

Julie Gralow, MD, speaks to the significance of the MONALEESA-3 study

video-image

Julie Gralow, MD, elaborates on how to differentiate CDK4/6 inhibitors

video-image

Tomasz M. Beer, MD, on how immunotherapy is being integrated into CRPC treatment algorithms

video-image

Tomasz M. Beer, MD, on how the PROSPER and SPARTAN studies are impacting standard of care

video-image

Tomasz M. Beer, MD, discusses the latest trends in the multimodality treatment of prostate cancer

video-image

Tomasz M. Beer, MD, on how to avoid under-diagnosing and over-diagnosing prostate cancer

video-image

Tomasz M. Beer, MD, discusses the central themes regarding prostate cancer here at ASCO 2018

video-image

Nicholas J. Vogelzang, MD, on imaging as an effective solution for prostate cancer diagnosis

video-image

Nicholas J. Vogelzang, MD, offers opinion on how MRI has improved diagnosing in prostate cancer

video-image

Nicholas J. Vogelzang, MD, on how we can avoid under-diagnosing & over-diagnosing prostate cancer

video-image

Richard Goldberg, MD, on the headline, "Immunotherapy Now Standard for Some Patients With CRC"

video-image

Richard Goldberg, MD, elaborates on the outcomes of the PRODIGY7 study in mCRC patients

video-image

Richard Goldberg, MD, on how the FIRE-3 data in CRC presented at ASCO 2018 reinforces CALGB 80405

video-image

Richard Goldberg, MD, considers the value of preoperative chemotherapy in pancreatic cancer

video-image

Richard Goldberg, MD, regarding the outcomes of the PA.6 clinical study in pancreatic cancer

video-image

Jennie Crews, MD, MMM, FACP, regarding key initiatives for the ACCC Immuno-Oncology Institute

video-image

Joan Schiller, MD, regarding Keynote trials from ASCO 2018 & the influence on choice of therapy

video-image

Joan Schiller, MD, considers the validity of Tumor Mutation Burden (TMB) as a biomarker

video-image

Joan Schiller, MD, on the impact of Keynotes 189 & 42 on drug sequencing regimens

video-image

Joan Schiller, MD, regarding the results of Keynote 42 presented at the 2018 ASCO Annual Meeting

video-image

Joan Schiller, MD, considers the continuation of pemetrexed maintenance

video-image

Joan Schiller, MD, offers her opinion on Keynote 189 & PDL-1 expression and patient selection

video-image

Jennie Crews, MD, MMM, FACP, outlines the mission of the ACCC Immuno-Oncology Institute

video-image

Douglas W. Blayney, MD, discusses the biggest takeaway regarding breast cancer here at ASCO 2018

video-image

Douglas W. Blayney, MD, on if the results of the TAILORx study practice changing

video-image

Douglas W. Blayney, MD, discusses the implications of the TAILORx study

video-image

Douglas W. Blayney, MD, discusses the MONALEESA-3 study in HR+/HER2- advanced breast cancer

video-image

Douglas W. Blayney, MD, on differentiating CDK4/6 Inhibitors and if they can be used interchangeably

video-image

Al Benson III, MD, FACP, on how tumor-sidedness impacts colorectal cancer treatment algorithms

video-image

Al Benson III, MD, FACP, discusses the role of I-O and immunotherapy combinations when treating CRC

video-image

Al Benson III, MD, FACP, tells us about the outcomes of the ECOG-ACRIN study

video-image

Jennie Crews, MD, MMM, FACP, on how community oncology is embracing biomarkers

video-image

Noa Biran, MD, on combination carfilzomib & daratumumab in revlimid-refractory multiple myeloma

video-image

Noa Biran, MD, considers whether VPd is effective in relapsed multiple myeloma

video-image

Noa Biran, MD, on the logistics involved in delivering CAR-T in the BB2121 study

video-image

Noa Biran, MD, on the impact of the BB2121 study in multiple myeloma

video-image

Noa Biran, MD, shares some of the exciting clinical advances presented at ASCO 2018

video-image

Sara M. Tolaney, MD, MPH on whether CDK4/6 inhibitors can be used interchangeably

video-image

Sara M. Tolaney, MD, MPH tells us about the outcomes of the MONARCH 2 study

video-image

David R. Gandara, MD, discusses drug sequencing as a result of Keynote 189 and 42 results

video-image

David R. Gandara, MD, on what will change about patient selection as a result of Keynote 42

video-image

David R. Gandara, MD, on continuing pemextrexed maintenance

video-image

David R. Gandara, MD, on whether Keynote 189 impacted view of PDL-1 expression and patient selection

video-image

David R. Gandara, MD, shares the benefits of using ramucirumab plus docetaxel in 2nd line NSCLC

video-image

David R. Gandara, MD, discusses exciting new developments in lung cancer here at ASCO 2018

video-image

Mohammad Jahanzeb, MD, FACP, discusses the impact of Keynote 189 & 42 on drug sequencing regimens

video-image

David I. Quinn, MD, on which metastatic RCC patients should receive a TKI as first-line therapy

video-image

Gary D. Steinberg, MD, discusses FGFR inhibitors in metastatic bladder cancer

video-image

Sara M. Tolaney, MD, MPH discusses the practice changing outcomes of the TAILORx study

video-image

Sara M. Tolaney, MD, MPH, discusses the fulvestrant + ribociclib arm of the MONALEESA-3 study

video-image

Sara M. Tolaney, MD, MPH, on whether the results of the TAILORx study are “practice changing”

video-image

Celestia S. Higano, MD, discusses new data being presented here at ASCO in metastatic CRPC

video-image

Celestia S. Higano, MD, discusses how MRI has improved the diagnosis of prostate cancer

video-image

Celestia S. Higano, MD, on imaging as a cost-effective solution for diagnosis of prostate cancer

video-image

Al Benson, MD, on what molecular markers are most important to test for when treating CRC patients

video-image

Real-World Evidence: Can It Drive Differentiation and Demonstrate 'Value'?

video-image

Real-World Evidence Today and Tomorrow: The Role of Key Stakeholders

video-image

Real-World Evidence Compared to Randomized Clinical Trials

video-image

Real-World Evidence as a Mechanism for Patient-Centric Care

video-image

Practical Issues When Treating With Immunotherapy

video-image

Beyond PD-L1: In Search of Better Biomarkers

video-image

Evolving Immunotherapy Combinations